Literature DB >> 19153149

Early seizure frequency and aetiology predict long-term medical outcome in childhood-onset epilepsy.

Matti Sillanpää1, Dieter Schmidt.   

Abstract

In clinical practice, it is important to predict as soon as possible after diagnosis and starting treatment, which children are destined to develop medically intractable seizures and be at risk of increased mortality. In this study, we determined factors predictive of long-term seizure and mortality outcome in a population-based cohort of 102 children. At the end of the 40-year median follow-up, since their first seizure before the age of 16 years, 95 (93%) of 102 patients had entered one or more one-year remissions (1YR). In contrast, 7 (7%) patients never experienced any 1YR and their epilepsy was considered drug-resistant. Two factors present early in the course of treatment were found to be associated with adverse outcome. Having weekly seizures during the first year of treatment carried an 8-fold risk [hazard ratio 8.2 (1.6-43.0), P = 0.0125] of developing drug resistant epilepsy and a 2-fold risk of never entering terminal 1YR [hazard ratio 2.7 (1.5-5.0), P = 0.0010]. Having weekly seizures prior to treatment only slightly increased the risk to never enter terminal 1YR [hazard ratio 1.7 (1.04-2.9), P = 0.0350]. Thirteen of 102 patients (13%) died during follow-up. Long-term mortality was 9-fold higher for patients with symptomatic epilepsy [hazard ratio 9.0 (1.8-44.8), P = 0.0071]. Mortality was not, however, increased by having weekly seizures prior to or during the first year of treatment versus fewer seizures. Early seizure frequency can predict long-term seizure control during antiepileptic drug treatment, but not mortality. Aetiology, however, is predictive of both seizure outcome and mortality in childhood-onset epilepsy. Using these criteria allows early identification of children destined to develop intractable epilepsy and increased mortality.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19153149     DOI: 10.1093/brain/awn357

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  30 in total

1.  New developments in antiepileptic drug resistance: an integrative view.

Authors:  Dieter Schmidt; Wolfgang Löscher
Journal:  Epilepsy Curr       Date:  2009 Mar-Apr       Impact factor: 7.500

Review 2.  Transporters in drug-refractory epilepsy: clinical significance.

Authors:  N Marchi; J Gonzalez-Martinez; M-T Nguyen; T Granata; D Janigro
Journal:  Clin Pharmacol Ther       Date:  2010-01       Impact factor: 6.875

Review 3.  Prognosis of intractable epilepsy: is long-term seizure freedom possible with medical management?

Authors:  Heidi Munger Clary; Hyunmi Choi
Journal:  Curr Neurol Neurosci Rep       Date:  2011-08       Impact factor: 5.081

Review 4.  Seizures and epilepsy: an overview for neuroscientists.

Authors:  Carl E Stafstrom; Lionel Carmant
Journal:  Cold Spring Harb Perspect Med       Date:  2015-06-01       Impact factor: 6.915

5.  Homeostatic bioenergetic network regulation - a novel concept to avoid pharmacoresistance in epilepsy.

Authors:  Detlev Boison; Susan A Masino; Jonathan D Geiger
Journal:  Expert Opin Drug Discov       Date:  2011-07       Impact factor: 6.098

6.  Pharmacoresistance and cognitive delays in children: a bidirectional relationship.

Authors:  Lara Jehi
Journal:  Epilepsy Curr       Date:  2013-03       Impact factor: 7.500

7.  Epilepsy: long-term rates of childhood-onset epilepsy remission confirmed.

Authors:  Matti Sillanpää; Dieter Schmidt
Journal:  Nat Rev Neurol       Date:  2015-01-27       Impact factor: 42.937

Review 8.  New avenues for anti-epileptic drug discovery and development.

Authors:  Wolfgang Löscher; Henrik Klitgaard; Roy E Twyman; Dieter Schmidt
Journal:  Nat Rev Drug Discov       Date:  2013-09-20       Impact factor: 84.694

9.  Epilepsy surgery in infants : Safety issues and developmental outcome.

Authors:  Gudrun Gröppel; Christian Dorfer; Anastasia Dressler; Angelika Mühlebner; Barbara Porsche; Thomas Czech; Daniela Prayer; Martha Feucht
Journal:  Wien Klin Wochenschr       Date:  2017-12-07       Impact factor: 1.704

Review 10.  Anti-epileptogenic clinical trial designs in epilepsy: issues and options.

Authors:  Dieter Schmidt; Daniel Friedman; Marc A Dichter
Journal:  Neurotherapeutics       Date:  2014-04       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.